RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Zealand Pharma A/S - Stock

Zealand Pharma A/S EBIT 2024

Zealand Pharma A/S EBIT

-523.07 M DKK

Ticker

ZEAL.CO

ISIN

DK0060257814

WKN

A0YJW7

In 2024, Zealand Pharma A/S's EBIT was -523.07 M DKK, a -6.8% increase from the -561.24 M DKK EBIT recorded in the previous year.

The Zealand Pharma A/S EBIT history

YEAREBIT (undefined DKK)
2029e-
2028e0.4
2027e-0.34
2026e1.7
2025e-0.48
2024e-0.52
2023-0.56
2022-0.78
2021-0.78
2020-0.6
2019-0.57
2018-0.46
2017-0.25
2016-0.1
2015-0.06
2014-0.07
2013-0.19
20120.03
20110.01
2010-0.11
2009-0.08
2008-0.04

Zealand Pharma A/S Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Zealand Pharma A/S, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Zealand Pharma A/S from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Zealand Pharma A/S’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Zealand Pharma A/S. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Zealand Pharma A/S’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Zealand Pharma A/S’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Zealand Pharma A/S’s growth potential.

Zealand Pharma A/S Revenue, EBIT and net profit per share

DateZealand Pharma A/S RevenueZealand Pharma A/S EBITZealand Pharma A/S Net Income
2029e3.98 B DKK0 DKK2.4 B DKK
2028e1.91 B DKK402.56 M DKK-1.08 B DKK
2027e1.06 B DKK-335.57 M DKK-835.79 M DKK
2026e1.18 B DKK1.7 B DKK429.41 M DKK
2025e819.92 M DKK-481.29 M DKK-571.15 M DKK
2024e195.73 M DKK-523.07 M DKK-968.31 M DKK
2023342.79 M DKK-561.24 M DKK-703.74 M DKK
2022103.99 M DKK-775.86 M DKK-1.2 B DKK
2021108.55 M DKK-782.14 M DKK-1.02 B DKK
2020192 M DKK-602.3 M DKK-846.73 M DKK
201941.33 M DKK-573.18 M DKK-571.54 M DKK
201837.98 M DKK-463.5 M DKK581.28 M DKK
2017136.32 M DKK-248.53 M DKK-274.41 M DKK
2016230.86 M DKK-96.31 M DKK-157.3 M DKK
2015187.68 M DKK-64.38 M DKK-113.96 M DKK
2014153.77 M DKK-73.54 M DKK-64.99 M DKK
20136.6 M DKK-185.6 M DKK-183.7 M DKK
2012223.6 M DKK32.4 M DKK36.4 M DKK
2011142.3 M DKK8.8 M DKK13.4 M DKK
201087.4 M DKK-108.7 M DKK-104.6 M DKK
200925.3 M DKK-80.6 M DKK-76.4 M DKK
200856.3 M DKK-44.7 M DKK-33.7 M DKK

Zealand Pharma A/S stock margins

The Zealand Pharma A/S margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Zealand Pharma A/S. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Zealand Pharma A/S.

  • 3 years

  • 5 years

  • 10 years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Zealand Pharma A/S's sales revenue. A higher gross margin percentage indicates that the Zealand Pharma A/S retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Zealand Pharma A/S's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Zealand Pharma A/S's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Zealand Pharma A/S's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Zealand Pharma A/S. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Zealand Pharma A/S's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Zealand Pharma A/S Margin History

Zealand Pharma A/S Gross marginZealand Pharma A/S Profit marginZealand Pharma A/S EBIT marginZealand Pharma A/S Profit margin
2029e94.41 %0 %60.21 %
2028e94.41 %21.04 %-56.44 %
2027e94.41 %-31.78 %-79.15 %
2026e94.41 %143.75 %36.27 %
2025e94.41 %-58.7 %-69.66 %
2024e94.41 %-267.24 %-494.72 %
202394.41 %-163.73 %-205.3 %
2022100 %-746.12 %-1,156.05 %
202189.89 %-720.56 %-937.99 %
2020100 %-313.7 %-441 %
201999 %-1,386.73 %-1,382.77 %
201894.41 %-1,220.47 %1,530.61 %
201794.41 %-182.31 %-201.3 %
201694.41 %-41.72 %-68.13 %
201594.41 %-34.3 %-60.72 %
201491.04 %-47.82 %-42.26 %
201394.41 %-2,812.12 %-2,783.33 %
201294.41 %14.49 %16.28 %
201194.41 %6.18 %9.42 %
201094.41 %-124.37 %-119.68 %
200994.41 %-318.58 %-301.98 %
200894.41 %-79.4 %-59.86 %

Zealand Pharma A/S Aktienanalyse

What does Zealand Pharma A/S do?

Zealand Pharma A/S is a biopharmaceutical company specializing in the discovery and development of therapeutics, particularly in the field of diabetes, gastrointestinal, and metabolic diseases. The company aims to improve the quality of life for patients with chronic conditions. Zealand Pharma's business model is based on the discovery, development, and commercialization of novel peptide-based therapeutics, utilizing their own technology platform and partnering with pharmaceutical industry collaborators. Their portfolio includes innovative product candidates such as the diabetes treatment Adlyxin and Lixisenatide, both GLP-1 agonists developed in collaboration with Sanofi. They also have products for the treatment of gastrointestinal and heart diseases. Zealand Pharma has a wide pipeline of product candidates at various stages of development, including for the treatment of obesity, fatty liver diseases, and other metabolic conditions. The company works closely with partners such as Sanofi, Boehringer Ingelheim, and Roche. Zealand Pharma is listed on NASDAQ OMX Copenhagen and employs over 200 people in Denmark and the USA. Overall, Zealand Pharma is an innovative biopharmaceutical company with a diverse portfolio of product candidates, focused on collaboration to accelerate product development and improve the quality of life for patients with chronic conditions. Zealand Pharma A/S ist eines der beliebtesten Unternehmen auf Eulerpool.com.

EBIT Details

Analyzing Zealand Pharma A/S's EBIT

Zealand Pharma A/S's Earnings Before Interest and Taxes (EBIT) represents the company's operating profit. It is calculated by deducting all operating expenses, including the cost of goods sold (COGS) and operating expenses, from the total revenue, but before accounting for interest and taxes. It provides insights into the company’s operational profitability, excluding the impacts of financing and tax structures.

Year-to-Year Comparison

A yearly comparison of Zealand Pharma A/S's EBIT can reveal trends in the company’s operational efficiency and profitability. An increase in EBIT over the years can indicate enhanced operational efficiency or growth in revenue, while a decrease might raise concerns about increased operating costs or declining sales.

Impact on Investments

Zealand Pharma A/S's EBIT is a significant metric for investors. A positive EBIT suggests that the company is generating enough revenue to cover its operating expenses, an essential aspect for assessing the company’s financial health and stability. Investors closely monitor EBIT to gauge the company’s profitability and potential for future growth.

Interpreting EBIT Fluctuations

Fluctuations in Zealand Pharma A/S’s EBIT can be due to variations in revenue, operating expenses, or both. An increasing EBIT indicates improved operational performance or increased sales, while a declining EBIT can signal rising operational costs or reduced revenue, prompting a need for strategic adjustments.

Frequently Asked Questions about Zealand Pharma A/S stock

How much did Zealand Pharma A/S achieve in EBIT for the current year?

In the current year, Zealand Pharma A/S has achieved an EBIT of -523.07 M DKK.

What is EBIT?

EBIT stands for Earnings Before Interest and Taxes and refers to the profit before interest and taxes of a company Zealand Pharma A/S.

How has the EBIT of Zealand Pharma A/S developed in recent years?

The EBIT of Zealand Pharma A/S has increased by -6.802% decreased compared to the previous year.

What does EBIT mean for investors?

EBIT provides investors with insights into a company's profitability as it reflects the profit before interest expenses and taxes.

Why is EBIT an important indicator for investors?

Since EBIT provides a more direct insight into a company's profit than net income, it is an important indicator for investors to assess the profitability of a company.

Why do EBIT values fluctuate?

EBIT values can fluctuate as they are influenced by various factors, such as revenue, costs, and tax effects.

What role does tax burden play in EBIT?

Tax burdens have a direct impact on a company's EBIT, as they are deducted from the profit.

How is EBIT presented in the balance sheet of the company Zealand Pharma A/S?

The EBIT of Zealand Pharma A/S is listed in the income statement.

Can EBIT be used as a single indicator for evaluating a company?

EBIT is an important indicator for evaluating a company, but additional financial ratios should also be considered to get a comprehensive picture.

Why is EBIT not equal to net profit?

The net profit of a company includes taxes and interest, while EBIT represents the profit before interest and taxes.

How much dividend does Zealand Pharma A/S pay?

Over the past 12 months, Zealand Pharma A/S paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Zealand Pharma A/S is expected to pay a dividend of 0 DKK.

What is the dividend yield of Zealand Pharma A/S?

The current dividend yield of Zealand Pharma A/S is .

When does Zealand Pharma A/S pay dividends?

Zealand Pharma A/S pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Zealand Pharma A/S?

Zealand Pharma A/S paid dividends every year for the past 0 years.

What is the dividend of Zealand Pharma A/S?

For the upcoming 12 months, dividends amounting to 0 DKK are expected. This corresponds to a dividend yield of 0 %.

In which sector is Zealand Pharma A/S located?

Zealand Pharma A/S is assigned to the 'Health' sector.

Wann musste ich die Aktien von Zealand Pharma A/S kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Zealand Pharma A/S from 7/6/2024 amounting to 0 DKK, you needed to have the stock in your portfolio before the ex-date on 7/6/2024.

When did Zealand Pharma A/S pay the last dividend?

The last dividend was paid out on 7/6/2024.

What was the dividend of Zealand Pharma A/S in the year 2023?

In the year 2023, Zealand Pharma A/S distributed 0 DKK as dividends.

In which currency does Zealand Pharma A/S pay out the dividend?

The dividends of Zealand Pharma A/S are distributed in DKK.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Zealand Pharma A/S

Our stock analysis for Zealand Pharma A/S Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Zealand Pharma A/S Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.